# DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.

> **NIH NIH N44** · BLUEWILLOW BIOLOGICS, INC. · 2020 · $2,916,500

## Abstract

Food allergy is an emerging health problem with increasing incidence and severity, particularly in children, and continuing throughout adulthood. Since 1990, the incidence of self-reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare system. With no approved therapeutics available, various forms of immunotherapy have been evaluated but generally do not facilitate long-term protection and can have adverse side effects. BlueWillow will apply its oil-in-water NanoVax nanoemulsion mucosal adjuvant (NE01) to formulate a vaccine against peanut allergy. In this SBIR project, Phase I will consist of formulation activities and the evaluation of efficacy in a mouse model of peanut allergy. In phase II, the project will assess the long-term protection in preclinical animal models and engage in IND-enabling activities.

## Key facts

- **NIH application ID:** 10250294
- **Project number:** 75N93019C00035-P00002-9999-1
- **Recipient organization:** BLUEWILLOW BIOLOGICS, INC.
- **Principal Investigator:** Ali I. Fattom
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,916,500
- **Award type:** —
- **Project period:** 2019-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10250294

## Citation

> US National Institutes of Health, RePORTER application 10250294, DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY. (75N93019C00035-P00002-9999-1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10250294. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*